http://ift.tt/eA8V8J
DALLAS–(BUSINESS WIRE)–Today Lantern Pharma Inc. announced the closure of its Series A equity financing of $3.7 million for the biotech company and its clinical-stage cancer treatments. This Series A closing was led by Bios Partners, GPG Ventures and other private investors. Lantern Pharma Inc. is a clinical-stage biotech focused exclusively on accelerating the cancer drug approval process using big data and artificial intelligence. Lantern’s strategy focuses on identifying partners or acquir
May 03, 2017 at 12:13AM
from
No comments:
Post a Comment